Relapsed or Refractory Follicular lymphoma (r/rFL) – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032


 Follicular lymphoma (FL), commonly referred to as indolent lymphoma, is the second most common type of non-Hodgkin lymphoma (NHL). After treatment, many FL patients fail to respond, and these tumors are categorized as refractory lymphomas. Some react with an initial positive change but then develop signs of recurrent tumor, called relapsed follicular lymphoma. Advanced stage disease is considered incurable and is characterized by a prolonged relapsing/remitting course. A significant minority have less favorable outcomes, particularly those with transformed or early progressive disease. The introduction of anti-CD20 monoclonal antibodies (mAb) such as rituximab and, more recently, type II anti-CD20 mAb, obinutuzumab, has revolutionized the management of FL, and anti-CD20 antibodies will likely remain at the forefront of the FL treatment armamentarium. But more recent insights demonstrating the intricate relationship between the FL tumor cell and its distinct immune microenvironment have led to a rapid accumulation of novel and innovative targeted therapies that harness the immune system’s power to attack the malignant cell.

 

FL affects approximately 3.7 in 10,000 individuals in the European Union (EU), below the EU threshold for orphan designation of 5 in 10,000 individuals.

The overall 10-year prevalence of FL is 25.2/100,000, with a higher prevalence in females than males (prevalence 26.2 vs. 24.1/100,000, respectively).

 

The competitive landscape of Relapsed or Refractory Follicular lymphoma (r/rFL) includes country-specific approved and pipeline therapies. Any asset/product-specific designation, review, and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights on Relapsed or Refractory Follicular lymphoma (r/rFL) across the 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Relapsed or Refractory Follicular lymphoma (r/rFL) Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Relapsed or Refractory Follicular lymphoma (r/rFL) – Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2021 To 2032

S. No    Asset               Company                                 Stage

1          Kymriah (tisagenlecleucel)         Novartis            Phase 2

2          Loncastuximab Tesirine ADC Therapeutics S.A.  Phase 2

3          Axicabtagene Ciloleucel Gilead Sciences            Phase 2

4          HMPL-689        Hutchison Medipharma Limited  Phase 2

5          Tazemetostat    Epizyme, Inc.    Phase 2

6          Zanubrutinib      BeiGene           Phase 2

7          Abexinostat       Xynomic Pharmaceuticals, Inc.  Phase 2

8          parsaclisib         Incyte Corporation         Phase 2

9          Bendamustine Hydrochloride      Seagen Inc.      Phase 2

10        Zandelisib         MEI Pharma, Inc.          Phase 2

Comments

Post a Comment

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Image
  Acne vulgaris, a prevalent pilosebaceous unit inflammatory skin disorder, follows a persistent course. Typically presenting as papules, pustules, or nodules, it primarily occurs on the face but can also impact the upper arms, trunk, and back. The development of acne results from the sebaceous glands' heightened sensitivity to normal androgen levels, aggravated by Cutibacterium acnes (formerly known as Propionibacterium acnes), a bacterial species that triggers inflammation. The pathogenesis of acne vulgaris involves a complex interplay of factors such as the activation of sebaceous glands by androgens, imbalances in the pilosebaceous follicle microbiome, and cellular immune responses. Genetic predisposition and dietary influences also contribute to the condition's onset and progression. The initial stage is the micro-comedo, a small plug primarily composed of corneocytes in the lower follicular infundibulum. Microcomedones evolve into various acne lesions, including closed co...
Read more

Herpes Simplex Virus (HSV) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
 Herpes simplex virus (HSV) causes an infection that affects the external genitalia, anal region, mucosal surfaces, and skin in other body parts. Herpes simplex virus is a ubiquitous, host-adapted pathogen that causes various disease states. There are two types of HSV with two distinct DNA viruses, type 1 (HSV-1) and type 2 (HSV-2). Both the types are closely related but differ epidemiologically. HSV-1 is traditionally associated with orofacial disease by affecting the mouth and lips with fever blisters and cold sores, whereas HSV-2 is associated traditionally with genital disease infecting genitals and rectum area with sores and is classified as STD (sexually transmitted disease). As HSV-1 is associated with genital infections more often than HSV-2, lesion location is not necessarily of viral type. HSV can spread through direct contact. Almost 80% of Herpes simplex infections are asymptomatic, while symptomatic infections can be characterized by significant morbidity and recurrenc...
Read more

HR+/HER2- Breast Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
Thelansis’s “HR+/HER2- Breast Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential HR+/HER2- Breast Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). KOLs insights of HR+/HER2- Breast Cancer across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs. HR+/HER2- Breast Cancer Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model,...
Read more